Anti-inflammatory properties of antidiabetic drugs: A 'promised land' in the COVID-19 era?
| العنوان: | Anti-inflammatory properties of antidiabetic drugs: A 'promised land' in the COVID-19 era? |
|---|---|
| المؤلفون: | Niki Katsiki, Ele Ferrannini |
| المصدر: | Journal of Diabetes and its Complications Journal of Diabetes and Its Complications |
| بيانات النشر: | Elsevier BV, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Endocrinology, Diabetes and Metabolism, Anti-Inflammatory Agents, Interleukin 6, 030209 endocrinology & metabolism, Comorbidity, 030204 cardiovascular system & hematology, Saxagliptin, Linagliptin, Bioinformatics, Article, Glucagon-like peptide-1 receptor agonists, Glucagon-Like Peptide-1 Receptor, C-reactive protein, 03 medical and health sciences, chemistry.chemical_compound, Lixisenatide, 0302 clinical medicine, Endocrinology, Risk Factors, medicine, Internal Medicine, Humans, Hypoglycemic Agents, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Inflammation, Canagliflozin, Ferritin, Dipeptidyl-Peptidase IV Inhibitors, Pioglitazone, SARS-CoV-2, business.industry, Semaglutide, Sitagliptin Phosphate, COVID-19, Metformin, Dipeptidyl peptidase 4 inhibitors, Diabetes Mellitus, Type 2, chemistry, business, Exenatide, Sodium-glucose co-transporter-2 inhibitors, Alogliptin, medicine.drug |
| الوصف: | Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin] were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic. Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin. Highlights • Inflammation is implicated in the development and severity of the coronavirus disease 2019 and diabetes. • C-reactive protein, interleukin-6 and ferritin were linked to poor glycemic control and worse COVID-19 outcomes. • There are limited and, in many cases, inconsistent data on the potential anti-inflammatory actions of antidiabetic drugs. • The most suggestive data are those on ferritin for the sodium glucose co-transporter-2 inhibitors. • Multiethnic trials are required to determine whether certain antidiabetic drugs exert inherent anti-inflammatory actions. |
| اللغة: | English |
| تدمد: | 1056-8727 |
| DOI: | 10.1016/j.jdiacomp.2020.107723 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c7d259d2b2320def71dbaf69d67c50fTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9c7d259d2b2320def71dbaf69d67c50f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10568727 |
|---|---|
| DOI: | 10.1016/j.jdiacomp.2020.107723 |